Company / Working Capital
Allogene Therapeutics, Inc. Working Capital History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$225.2M
FY2025
5-year range
$225.2M / $433.1M
FY2021-FY2025
Trend
-15.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 3 consecutive years, from $433M in FY2022 to $225M in FY2025.
Based on SEC 10-K filings.
$225M in FY2025 with a 3-year CAGR of -19.6%.
Declined from $422M to $225M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -19.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Allogene Therapeutics, Inc.'s working capital has declined for 3 consecutive years.
- 3-year CAGR of -19.6%, indicating a declining trend.
- In FY2025, working capital decreased 15.9% year-over-year.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $225.2M | -15.9% |
| FY2024 | $267.9M | -36.5% |
| FY2023 | $422.0M | -2.6% |
| FY2022 | $433.1M | +2.4% |
| FY2021 | $423.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026